Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 3/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.33 |
| ▸ | RELA | Q04206 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325805 | 0.95 | CYP1A2 (0.38) | CYP1A2ALDH1A1 | |
| SCHEMBL6325329 | 0.93 | CYP1A2 (0.40) | CYP1A2ALDH1A1 | |
| SCHEMBL6327304 | 0.86 | CYP1A2 (0.41) | NFKB1NFKB2RELACYP1A2MAPT | |
| SCHEMBL6332606 | 0.85 | MAPT (0.38) | NFKB1NFKB2RELACYP1A2MAPT | |
| SCHEMBL6325480 | 0.84 | PIK3CD (0.38) | MMEPIK3CD | |
| SCHEMBL6327995 | 0.82 | CYP1A2 (0.44) | NFKB1NFKB2RELACYP1A2MAPT | |
| SCHEMBL6326280 | 0.80 | CYP1A2 (0.47) | CYP1A2ALDH1A1 | |
| SCHEMBL6325406 | 0.80 | CYP1A2 (0.47) | CYP1A2ALDH1A1 | |
| SCHEMBL6325069 | 0.80 | CYP1A2 (0.38) | CYP1A2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6332614 | 0.80 | CYP1A2 (0.46) | CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | ZEON CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1420005-A1 | CYCLOPENTANONE DERIVATIVE | Zeon Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | PTGIS, CYP51A1, TRPA1 | NFKB1 853/4885NFKB2 897/4885RELA 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.